Crisaborole Brand Name– EUCRISA
What is Crisaborole
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Because crisaborole is administered topically, it avoids the gastrointestinal side effects that are associated with apremilast, an orally administered PDE-4 inhibitor. The most commonly reported adverse event with crisaborole is application site pain, which frequently develops after the first dose and resolves within 1 day.
Approval was based on the results of 2 double-blinded, vehicle-controlled trials involving 1,522 patients (ages 2 to 79 years) with mild to moderate atopic dermatitis.
The primary endpoint, defined as an Investigator’s Static Global Assessment score of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline, was achieved by more crisaborole-treated patients (31.4% to 32.8%) than those receiving vehicle ointment (18% to 25.4%).
In addition, the time to reach the primary endpoint occurred earlier in patients treated with crisaborole than in those treated with the vehicle.
- atopic dermatitis
For the treatment of mild to moderate atopic dermatitis
- contact dermatitis
- skin irritation
- laboratory monitoring not necessary
- ocular exposure
- ophthalmic administration
- vaginal administration
There are no drug interactions associated with Crisaborole products.